Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 26:13:1079575.
doi: 10.3389/fonc.2023.1079575. eCollection 2023.

Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016

Miao Liu  1 , Lingge Wei  1 , Wei Liu  1 , Shupeng Chen  1 , Meichao Guan  1 , Yingjie Zhang  1 , Ziyu Guo  1 , Ruiqi Liu  2 , Peng Xie  1
Affiliations

Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016

Miao Liu et al. Front Oncol. .

Abstract

Objectives: We aimed to determine trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors (GI-NETs) from 1977 to 2016, and then analyze the potential risk factors including sex, age, race, grade, Socioeconomic status (SES), site, and stage.

Methods: Data were obtained from Surveillance, Epidemiology, and End Results Program (SEER) database. Kaplan-Meier survival analysis, relative survival rates (RSRs), and Cox proportional risk regression model were used to evaluate the relationship between these factors and prognosis.

Results: Compared with other sites, the small intestine and rectum have the highest incidence, and the appendix and rectum had the highest survival rate. The incidence was higher in males than in females, and the survival rate in males was close to females. Blacks had a higher incidence rate than whites, but similar survival rates. Incidence and survival rates were lower for G3&4 than for G1 and G2. Age, stage, and grade are risk factors.

Conclusions: This study described changes in the incidence and survival rates of GI-NETs from 1977 to 2016 and performed risk factor analyses related to GI-NETs.

Keywords: gastrointestinal neuroendocrine tumors; incidence; relative; risk factors; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Incidence of Patients diagnosed with GI-NETs at the original nine SEER sites between 1977 and 2016. The incidence and number of GI-NETs cases are shown by age group (total and age 0-44 years, 45-59 years, 60-74 years, and over 75 years) and four-time periods. Incidence (A, C, E, G, I) and number (B, D, F, H, J) of GI-Nets cases were grouped by sex, SES, race, and grade, respectively.
Figure 2
Figure 2
The numbers of patients with GI-NETs of SES in different races across four decades (A, C, E, G, I); Changes in the distribution of SES in different races across four decades (B, D, F, H, J).
Figure 3
Figure 3
Incidence of Patients diagnosed with GI-NETs at the original nine SEER sites between 1977 and 2016. The number (A, B) and incidence (C) of GI-Nets cases are shown by site group (stomach, small intestine, appendix, colon, rectum) and four-time periods.
Figure 4
Figure 4
Trends in 10-year relative survival (A, C, E, G, I) and Kaplan-Meier survival analysis (B, D, F, H, J) for PATIENTS with GI-NETs during 1977-1986 (orange), 1987-1996 (blue), 1997-2006 (black), and 2007-2016 (gray), grouped by age (total and age 0-44 years, 45-59 years, 60-74 years and over 75 years).
Figure 5
Figure 5
Trends in relative survival rate (A–C) and Kaplan–Meier survival curves (D–G) for patients with GI-NETs at 9 SEER sites according to sex group (male and female) in 1977–1986, 1987–1996, 1997–2006, and 2007-2016.
Figure 6
Figure 6
Trends in relative survival rate (A–C) and Kaplan–Meier survival curves (D–G) for patients with GI-NETs at 9 SEER sites according to race group (whites, blacks, and others) in 1977–1986, 1987–1996, 1997–2006, and 2007-2016.
See this image and copyright information in PMC

References

    1. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA: A Cancer J Clin (2018) 68:471–87. doi: 10.3322/caac.21493 - DOI - PubMed
    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol (2017) 3:1335–42. doi: 10.1001/jamaoncol.2017.0589 - DOI - PMC - PubMed
    1. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the united states: a seer analysis. J Cancer (2012) 3:292–302. doi: 10.7150/jca.4502 - DOI - PMC - PubMed
    1. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures–the public health disparities geocoding project. Am J Public Health (2003) 93:1655–71. doi: 10.2105/ajph.93.10.1655 - DOI - PMC - PubMed
    1. Krieger N, Chen JT, Waterman PD, Soobader M-J, Subramanian SV, Carson R. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the public health disparities geocoding project. Am J Epidemiol (2002) 156:471–82. doi: 10.1093/aje/kwf068 - DOI - PubMed

LinkOut - more resources